Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Endometrium cancer diagnose reagent, reagent kit and controlling medicament

A technology of diagnostic reagents and drugs, applied in the field of tumor molecular biology, can solve the problems of no diagnostic reagents and kits for the prevention and treatment of endometrial cancer, and no diagnostic reagents and kits for endometrial cancer, so as to improve the survival rate , the effect of broad application prospects

Inactive Publication Date: 2008-09-10
SICHUAN UNIV
View PDF0 Cites 31 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] So far, there are no relevant reports on diagnostic reagents and kits for early diagnosis of endometrial cancer by detecting the expression level of human cyclophilin A, and there is no report on the prevention and treatment of endometrial cancer by changing its expression level. Reports about the purpose

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Endometrium cancer diagnose reagent, reagent kit and controlling medicament
  • Endometrium cancer diagnose reagent, reagent kit and controlling medicament
  • Endometrium cancer diagnose reagent, reagent kit and controlling medicament

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0041] Example 1 Preliminary determination of human cyclophilin A protein as a protein related to the occurrence and development of endometrial cancer

[0042] 1. Sources of endometrioid adenocarcinoma and normal endometrial tissue specimens in proliferative phase

[0043]The endometrial cancer tissue specimens used in this example were collected from endometrial cancer patients undergoing surgical treatment in the Department of Obstetrics and Gynecology, West China Second Hospital, Sichuan University, from March to May 2006. The age distribution of the patients was between 45 and 60 years old, with an average age of 52.75±4.71 years old. All patients received no chemotherapy or radiotherapy before operation, and the postoperative pathological diagnosis was clear with complete clinical data. Normal endometrial specimens were collected from patients with benign diseases such as uterine fibroids who underwent surgical treatment in the Obstetrics and Gynecology Department of the...

Embodiment 2

[0064] Verification that the cyclophilin A protein is a protein related to the occurrence and development of endometrial cancer

[0065] RT-PCR and Western Blot were used to verify the expression difference of human cyclophilin A between endometrial carcinoma and normal endometrium at mRNA and protein levels.

[0066] 1. Reagent source

[0067] RT-PCR related reagents: Trizol Reagent was purchased from Invitrogen; Oligo(dT), MgCl 2 , dNTPmix, RNase Inhibitor, AMV-Optimized Taq, AMV RTase XL, etc. were purchased from TaKaRa Company.

[0068] Western Blot related reagents: rabbit anti-human human cyclophilin A polyclonal antibody was purchased from Upstate; mouse anti-human β-actin monoclonal antibody was purchased from Santa Cruz; horseradish peroxidase (HRP)-labeled goat anti-rabbit IgG and goat anti-mouse IgG (secondary antibody) were purchased from Beijing Zhongshan Jinqiao Biotechnology Co., Ltd.; protein pre-stained Marker was purchased from MBI Company; nitrocellulose (...

Embodiment 3

[0109] Example 3. Immunohistochemical Analysis of the Expression of Human Cyclophilin A in Endometrial Carcinoma and Normal Endometrium Tissue

[0110] 1. Source of tissue samples

[0111] Paraffin specimens were obtained from the Department of Pathology, West China Second Hospital, Sichuan University. Among them, endometrial cancer specimens were collected from 52 patients with endometrial cancer who underwent surgery in the Department of Obstetrics and Gynecology, West China Second Hospital, Sichuan University, from March 2005 to March 2006. The pathological diagnosis was all endometrioid adenocarcinoma, including 20 cases of well-differentiated adenocarcinoma, 20 cases of moderately differentiated adenocarcinoma, and 12 cases of poorly differentiated adenocarcinoma; surgical pathological staging was stage I in 40 cases, stage II in 8 cases, and stage III in 4 cases. example. Normal endometrial samples were collected from 39 patients with benign diseases such as uterine fi...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the field of the tumor molecule biology, in particular to a diagnosis reagent, a reagent knit and prevention and cure drugs of endometrial carcinoma, which provides a new diagnosis reagent and medicine for the early diagnosis and the prevention of endometrial carcinoma, and also provides a new method for filtering the medicine used for preventing endometrial carcinoma. The diagnosis reagent for endometrial carcinoma of the invention contains a reagent which can test the expressing level of a human cyclophilin A protein or the content of the mRNA of genes of the human cyclophilin A protein. The medicine which can prevent endometrial carcinoma of the invention includes: the expressing carrier of a shPNA molecule which can express the human cyclophilin A, etc. can change the expressing level of the human cyclophilin A protein or the mRNA content of the genes of the human cyclophilin A protein. The diagnosis reagent of the invention can be used for the early diagnosis of endometrial carcinoma, which has a wide application prospect.

Description

technical field [0001] The invention belongs to the field of tumor molecular biology, and in particular relates to a diagnostic reagent, kit and prevention and treatment medicine for endometrial cancer. Background technique [0002] As one of the three major malignant tumors of the female reproductive tract, endometrial cancer accounts for 20-30% of malignant tumors of the female reproductive tract. With the development of society and the extension of the average life expectancy of human beings, the incidence of endometrial cancer is increasing year by year and accompanied by a younger trend. If endometrial cancer can be diagnosed early and treated reasonably, its prognosis is generally good. The main clinical manifestation of endometrial cancer is irregular vaginal bleeding. Unlike other tumors such as ovarian cancer, the clinical diagnosis mainly relies on diagnostic curettage. However, patients with breast-feeding or invasive endometrial cancer have weak uterine walls. ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): G01N33/68G01N33/577C12Q1/68
Inventor 赵霞李征宇黄灿华魏于全
Owner SICHUAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com